Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. The participant had a diagnosis of PKAN as indicated by confirmed mutations in the pantothenate kinase 2 gene.~2. The participant was male or female aged 6 to 65 years, inclusive.~3. The participant had a score of ≥ 6 on the PKAN-specific activities of daily living measure.~Exclusion Criteria:~1. The participant had required regular or intermittent invasive ventilatory support to maintain vital signs within 24 weeks prior to randomization.~2. The participant had a deep brain stimulation device implanted within 6 months prior to screening.~3. The participant had taken deferiprone within 30 days prior to screening.~4. The participant was unable to maintain stable doses of allowed concomitant medications for the first 24 weeks of the study.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Fosmetpantotenate (Type: EXPERIMENTAL): Administered as powder for reconstitution.
- Placebo (Type: PLACEBO_COMPARATOR): Administered as powder for reconstitution.

Based on this trial design, predict the completion outcome and termination type (if applicable).